Abstract
Objectives
Pain is one of the most common side effects of transcatheter arterial chemoembolization (TACE) treatment. This study aimed to assess the analgesic effect of parecoxib sodium for postoperative pain control in patients with inoperable hepatocellular carcinoma (HCC) undergoing TACE.
Materials and methods
This randomized placebo-controlled prospective clinical study was conducted at a single cancer centre. Patients were randomly assigned to receive parecoxib sodium (experimental group; n = 60) or 0.9 % sodium chloride (control group; n = 60) 1 h before TACE and once every 12 h for 2 days after TACE. Pain level, morphine consumption, adverse events, and quality of life were evaluated and compared between the two groups.
Results
Pain scores, percentage distribution of pain categories, and morphine consumption were significantly lower in the experimental group than in the control group (P < 0.05). Fever score comparisons revealed significantly better body temperature balance in the experimental group than in the control group (P = 0.024). Quality-of-life scores in the experimental group were significantly better than those in the control group (P < 0.05).
Conclusions
Our results demonstrate that the perioperative administration of parecoxib significantly improved its effectiveness in the control of postoperative pain after TACE.
Key Points
• Perioperative administration of parecoxib is effective for control of pain after TACE.
• COX-2 inhibitors provide effective and safe pain control.
• Parecoxib helps improve quality-of-life after TACE for patients with inoperable hepatocellular carcinoma.
Similar content being viewed by others
Abbreviations
- BCLC:
-
Barcelona Clinic Liver Cancer
- COX:
-
cyclooxygenase
- HCC:
-
hepatocellular carcinoma
- NSAIDs:
-
nonsteroidal anti-inflammatory drugs
- NRS:
-
Numeric Rating Scale
- TACE:
-
transcatheter arterial chemoembolization
References
Ikeda K, Kobayashi M, Kawamura Y et al (2011) Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model. Liver Int 5:692–699
Ikeda K, Kawamura Y, Kobayashi M et al (2014) Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model. Oncology 5–6:295–302
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 2:397–401
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 9319:1734–1739
Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 1:47–54
Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2:461–469
Ikeda M, Arai Y, Park SJ et al (2013) Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol 4:490–500
Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 3:1020–1022
Arii S, Sata M, Sakamoto M et al (2010) Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the japan society of hepatology (2009). Hepatol Res 7:667–685
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 1:6–25
Zhou B, Wang J, Yan Z, Shi P, Kan Z (2012) Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. Radiology 3:1014–1021
Momeni M, Crucitti M, De Kock M (2006) Patient-controlled analgesia in the management of postoperative pain. Drugs 18:2321–2337
Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 4:442–452
Jirarattanaphochai K, Thienthong S, Sriraj W et al (2008) Effect of parecoxib on postoperative pain after lumbar spine surgery: a bicenter, randomized, double-blinded, placebo-controlled trial. Spine (Phila Pa 1976) 2:132–139
Hubbard RC, Naumann TM, Traylor L, Dhadda S (2003) Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth 2:166–172
Duseja A (2015) Staging of hepatocellular carcinoma. J Clin Exp Hepatol Suppl 3:S74–79
National Cancer Institute (2009) Common Terminology Criteria for dverse Events (CTCAE) Version 4.0. v403: June 14, 2010
Okusaka T, Kasugai H, Shioyama Y et al (2009) Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 6:1030–1036
Peng ZW, Zhang YJ, Chen MS et al (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 4:426–432
Lee SH, Hahn ST, Park SH (2001) Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: its effectiveness and optimal timing of administration. Cardiovasc Intervent Radiol 6:368–371
Fiorentini G, Aliberti C, Benea G et al (2008) TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 88:2077–2082
Cepeda MS, Tzortzopoulou A, Thackrey M, Hudcova J, Arora Gandhi P, Schumann R (2010) Adjusting the pH of lidocaine for reducing pain on injection. Cochrane Database Syst Rev 12, CD006581
Zhu Y, Wang S, Wu H, Wu Y (2014) Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study. Eur J Orthop Surg Traumatol 3:395–401
Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC (2003) Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 4:950–956
Malan TP Jr, Gordon S, Hubbard R, Snabes M (2005) The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. Anesth Analg 2:454–460
Buvanendran A, Kroin JS, Tuman KJ et al (2003) Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 18:2411–2418
Gan TJ, Joshi GP, Viscusi E et al (2004) Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 6:1665–1673, table of contents
Crile GW (1913) The kinetic theory of shock and its prevention through anociassociation. Lancet 2:7–16
Woolf CJ, Wall PD (1986) Morphine-sensitive and morphine-insensitive actions of C-fibre input on the rat spinal cord. Neurosci Lett 2:221–225
Brennan TJ, Umali EF, Zahn PK (1997) Comparison of pre- versus post-incision administration of intrathecal bupivacaine and intrathecal morphine in a rat model of postoperative pain. Anesthesiology 6:1517–1528
Hayakawa K, Tanikake M, Kirishima T et al (2014) The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol 5:1105–1111
Vogl TJ, Zangos S, Balzer JO et al (2007) Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results. Röfo 11:1113–1126
Acknowledgments
The scientific guarantor of this publication is Ming Zhao. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. No complex statistical methods were necessary for this paper. Institutional Review Board approval was obtained. Written informed consent was obtained from all subjects (patients) in this study. Methodology: prospective, randomised controlled trial, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ning Lv and Yanan Kong contributed equally to this work.
Rights and permissions
About this article
Cite this article
Lv, N., Kong, Y., Mu, L. et al. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol 26, 3492–3499 (2016). https://doi.org/10.1007/s00330-016-4207-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-016-4207-8